A proprietary process to identify small-molecule combinations for activating progenitor cells

Discovery in the right context
Traditional drug screening uses cells that may not reflect the complex biology of tissue-specific cell types in the body. We develop primary progenitor cell assays that are designed to maintain these cells in their natural state to increase the likelihood of successful drug discovery and translation into an effective, tissue-specific therapeutic.

Decoding and controlling activation pathways for progenitor cells
Using our insights into progenitor cell signaling and aging, we work to identify biological pathways that may activate a specific progenitor cell. We then select and apply proprietary combinations of small molecules to modulate the chosen biological pathways to activate these progenitors.

Using these small-molecule combinations, we and our collaborators have applied this discovery process to identify compounds that activate progenitor cells in numerous tissues.

As each tissue is unique in its biological needs, our approach allows for the development of treatments for specific tissue ailments throughout the body. Our strategy is to use this approach to deliver new therapeutics in indications beyond hearing loss, including diseases of the central nervous system, muscle, gastrointestinal tract, skin and bone.